We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
10th - 11th June 2024 - Organised by Longeity Technology who hold 3%. Gla ;-)
New international event program launches to bring longevity entrepreneurs and investors together.
Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.
The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.
Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.
“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”
Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.
The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.
“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.
“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”
“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.
“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”
Major Shareholders
ERIC LEIRE 124,000,000 35.5%
PREMIER MITON 32,000,000 9.2%
ARIAN BEESTON 17,475,000 5.0%
JONATHAN MARK SWANN 16,874,000 4.8%
SAMANTHA BAUER 14,500,000 4.1%
LONGEVITY TECH FUND 10,499,998 3.0%
SARAH BEESTON 10,000,000 2.9%
Very impressive, this is going to bounce big very soon. Gl :-)
Thats 400k! Strong show of support!
MY SYSTEM reporting wrong he increased
MARM swan reduced great that it was pushed up for the sells
Good to see Mr Swann increase his holding! Orders being filled in the background, are premier Miton still buying but now from open market?
Good to see Swann increase his position from 3 to 5%.
Strong show of confidence that!
Eric's £50k share subscription declared along with another 1.8% for Jonathan Swan who declared his 3% back in March. The smart Money is accumulating. Gla :-)
Good to see the bulk buys still going through and stock being teased off weak hands.
Q2 and Q3 look set to be bumper!
Only the beginning!
Or que up to have some vax shots of that special brew SIRT6!
Hopefully the insiders who bought the subscription will also be buying open market with the new tax year and we’ll see a serious move now!
Great to see strong buying yet again. More shares going into serious investors hands. Free float shrinking as the days pass! Rerate
Great churn into sticky hands no doubt!
It's going to big...On and UP!!! Gla :-)
Good luck all
Let’s get things moving now :)
Cheers Porter, an excellent and informative interview and very encouraging on prospects and potential going forward. Exciting times ahead. Gl :-)
Interview with Zak Mir:
https://m.youtube.com/watch?v=FJOC1ciauAg
- US fast tracking Nash trials
- 100,000 patients on liver transplant list in US alone
- talk of further US institutions coming in
- delivering Nash treatment like a vaccination - think how much money was made on covid…
You would presume we are at the front of the list!
GLA
Great find Northeast and exciting news for Genflow. Gl :-)
First in human proof-of-concept Phase I/ II Trial in NASH
NASH or Non-Alcoholic Steatohepatitis is a liver disease with a significant unmet medical need. Effecting an estimated 35 million people worldwide, it is the most chronic liver condition in the West and patient numbers are growing rapidly. It is the leading cause of liver transplants due to the lack of approved therapies with the market for NASH therapy expected to reach $27.2B by 2029.
Recent pre-clinical programs have highlighted the adipogenic, anti-fibrotic, and anti-tumoral effects of GF-1002 positioning it as a promising treatment candidate for NASH.
By targeting NASH, Genflow Biosciences stands to benefit from a clear regulatory pathway that could lead to accelerated development and the potential for conditional fast-track approval.
The European Medicines Agency (EMA) said in a new reflection paper that it will consider granting conditional marketing approval to sponsors developing treatments for non-alcoholic steatohepatitis (NASH) based on the use of intermediate endpoints to address a high unmet need for these products.
The paper addresses non-cirrhotic NASH, fibrosis stage 2 and 3, and cirrhotic NASH (fibrosis stage 4).
EMA said the paper outlines a “preliminary” development strategy for these products, as their experience in this space is still evolving.
EMA said that NASH “is considered the progressive, necro-inflammatory phenotype of non-alcoholic fatty liver disease (NAFLD), which itself is the most prevalent chronic liver disease worldwide with an estimated prevalence in the Western world of around 25%, and it is estimated that about 20-50% of these suffer from NASH.”
Despite the prevalence of the disease, there are no approved treatments for NASH in the EU. In the US, the Food and Drug Administration (FDA) on 14 March approved Madrigal Pharmaceuticals Rezdiffra (resmetirom) for treating adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis).
EMA said that “due to the unmet medical need in the field, a strategy to obtain an early, conditional approval (conditional marketing authorisation; CMA) of new compounds based on these intermediate endpoints could be considered.”
This strategy will only be acceptable if an unmet need is still present, a positive benefit-risk ratio can be concluded, and the applicant can provide comprehensive data post-marketing.
For non-cirrhotic NASH, fibrosis stage 2 and 3, acceptable intermediate endpoints would be:
The resolution of NASH – with the presence of any grade of steatosis, and no ballooning, only minimal (grade 1) lobular inflammation and no worsening of the stage of fibrosis.
The improvement of fibrosis by at least 1 stage without any worsening of NASH, and no worsening of ballooning and lobular inflammation, and no more than 1 grade increase in steatosis.
For cirrhotic NASH, fibrosis stage 4, or compensated cirrhosis, the reversal of cirrhosis can be considered an intermediate endpoint. “The endpoint would need to exclude the occurrence of any decompensation event, an increase in MELD [Model for End-Stage Liver Disease] as well as a deterioration (or re-occurrence) of features of NASH activity (inflammation, ballooning, and fat) at the same time (Improvement of cirrhosis by at least one fibrosis grade without occurrence of a decompensation event and without deterioration of MELD and NAS-score).
The paper will go into effect on 1 October 2024.
Love how indirectly he calls out the crooks from FLV right at the beginning.
All good here now going forward.
Absolute steal at this price now.